Search
Research
Baseline incidence of adverse birth outcomes and infant influenza and pertussis hospitalisations prior to the introduction of influenza and pertussis vaccinationThese baseline data are essential to assess the safety and effectiveness of influenza and pertussis vaccinations in pregnant women from the NT
Research
AusVaxSafetyChristopher Peter Peter Tom Blyth Jacoby Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BA (Hons) MSc MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid
Research
Prevalence and determinants of influenza vaccine coverage at tertiary pediatric hospitalsThis study aimed to examine the uptake of influenza vaccination amongst a cohort of Australian children and factors associated with vaccine acceptance.
Research
The influence of incomplete case ascertainment on measures of vaccine efficacyA biologically active vaccine may produce a low measured vaccine efficacy under a range of epidemiological, vaccine-related and logistical conditions
Research
Systemic antibiotics for chronic suppurative otitis mediaTo assess the effects of systemic antibiotics for people with chronic suppurative otitis media.
Research
Parental pre-pregnancy BMI is a dominant early-life risk factor influencing BMI of offspring in adulthoodParental pre-pregnancy body mass index and rapid early-life weight gain predispose offspring to obesity in adulthood
Research
Risk factors associated with RSV hospitalisation in the first 2 years of life, among different subgroups of children in NSWData on risk factors for respiratory syncytial virus (RSV)-associated hospitalisation in Australian children may be informative for preventive measures.
Research
Australian trachoma surveillance annual report, 2013National Trachoma Surveillance and Reporting Unit to collate, analyse and report trachoma prevalence data and document trachoma control strategies in Australia
Research
High burden of RSV hospitalization in very young children: a data linkage studyRSV was associated with substantial burden of childhood hospitalization specifically in children aged <3 months and in Indigenous children and pre-term children
Research
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adultsUntreated hepatitis C virus (HCV) infection can result in cirrhosis and hepatocellular cancer. Direct-acting antiviral (DAA) therapies are highly effective and have few side effects compared to older interferon-based therapy. Despite the Australian government providing subsidised and unrestricted access to DAA therapy for chronic HCV infection, uptake has not been sufficient to meet the global target of eliminating HCV as a public health threat by 2030.